Biodexa Announces Support for Life’s a Polyp Foundation First U.S. Patient Advocacy Group for FAP Patients
March 9, 2026 Biodexa Announces Support for Life’s a Polyp FoundationFirst U.S. Patient Advocacy Group for FAP Patients Cardiff, UK...
March 9, 2026 Biodexa Announces Support for Life’s a Polyp FoundationFirst U.S. Patient Advocacy Group for FAP Patients Cardiff, UK...
Tenaya’s Highly Selective HDAC6 Inhibitor TN-301 Outperformed Approved Pan-HDAC Inhibitor Givinostat in Improving Muscle Function and Correcting Drivers of DMD...
-- The Phase 2b study to assess enobosarm’s ability to preserve lean mass, physical function, and bone as well as...
Financing led by Certain of the Company’s Directors and Executive OfficersFORT LAUDERDALE, Fla., March 09, 2026 (GLOBE NEWSWIRE) -- SS...
– Company to Host Conference Call on March 12, 2026, at 4:30 p.m. ET – SAN DIEGO, March 09, 2026...
The developers of sustained acoustic medicine technology and the sam® wearable ultrasound device continue mission of advancing care for arthritis...
Company to hold a conference call at 8:00 a.m. ETDURHAM, N.C., March 09, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc....
TORONTO, March 09, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device...
EventHorizonIQ, available now at https://eventhorizoniq.com/pricing, provides investors and risk professionals with institutional-grade cross-asset regime intelligence Subscription launch represents first proprietary product...
Strengthening balance sheet and capitalization is a key Jaguar priorityCompany continues its sharp, strategic focus on global development program for...
KELOWNA, BC / ACCESS Newswire / March 9, 2026 / Avant Brands Inc. (TSX:AVNT)(OTCQX:AVTBF)(FRA:1BU0) ("Avant" or the "Company"), is pleased...
Latest New Market Entry Caps Year of Strategic Expansion and Positions Company for Strong 2026 DALLAS, TEXAS / ACCESS Newswire...
--- Precision Bb Targeting, Robust Efficacy, Transfusion Independence, Excellent Safety in Phase II PNH Study, and Subcutaneous Administration Key Highlights:...
GLP-1 agonist market expected to grow from $70B in 2025 to $201B in 20301Proprietary Forzet formulation provides pharmacists, physicians and...
Approved dosing regimen reduces the burden for eligible patients, their families, and the broader healthcare system by extending infusion interval...
TEL AVIV, March 09, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage...
NEEDHAM, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical...
Data support potential of isaralgagene civaparvovec as a one-time, well tolerated and durable Fabry disease gene therapy to provide meaningful,...
LEXINGTON, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical...
Closing of additional $50 million tranche of $100 million equity private placement after achievement of clinical milestone for rondecabtagene autoleucelSmital...